Abstract
Bortezomib is the first-in-class proteasome inhibitor which has been used worldwide for the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib is under evaluation as a single agent or in combination with other drugs for solid cancers and stem cell transplantation in clinical settings. However, adverse effects and drug resistance have been observed in patients, which is now emerging as a great challenge for the extended application of bortezomib. In this review, we will comprehensively discuss the development of bortezomib, the mechanism underlying its therapeutics, adverse effects and resistance. Second generation of bortezomib and its future directions will also be discussed.
Keywords: Proteasome inhibitor, bortezomib, adverse effect, resistance.
Current Pharmaceutical Design
Title:Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction
Volume: 19 Issue: 18
Author(s): Biyin Cao, Jie Li and Xinliang Mao
Affiliation:
Keywords: Proteasome inhibitor, bortezomib, adverse effect, resistance.
Abstract: Bortezomib is the first-in-class proteasome inhibitor which has been used worldwide for the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib is under evaluation as a single agent or in combination with other drugs for solid cancers and stem cell transplantation in clinical settings. However, adverse effects and drug resistance have been observed in patients, which is now emerging as a great challenge for the extended application of bortezomib. In this review, we will comprehensively discuss the development of bortezomib, the mechanism underlying its therapeutics, adverse effects and resistance. Second generation of bortezomib and its future directions will also be discussed.
Export Options
About this article
Cite this article as:
Cao Biyin, Li Jie and Mao Xinliang, Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction, Current Pharmaceutical Design 2013; 19 (18) . https://dx.doi.org/ 10.2174/13816128113199990338
DOI https://dx.doi.org/ 10.2174/13816128113199990338 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lumiflavin Enhances the Effects of Ionising Radiation on Ovarian Cancer Stem-Like Cells by Inhibiting Autophagy
Anti-Cancer Agents in Medicinal Chemistry BRCA Unclassified Variants: How Can They be Classified?
Current Women`s Health Reviews Zoledronic Acid -a Multiplicity of Anti-Cancer Action
Current Medicinal Chemistry The Akt-mTOR Pathway in Down’s Syndrome: The Potential Use of Rapamycin/Rapalogs for Treating Cognitive Deficits
CNS & Neurological Disorders - Drug Targets CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Recent Advances in Enone and NO-Releasing Derivatives of Oleanolic Acid with Anti-cancer Activity
Mini-Reviews in Organic Chemistry Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry The ATP-driven Hsp60 Machinery: Biological and Clinical Implications
Current Immunology Reviews (Discontinued) Mandatory Reporting of Coronary Artery Calcifications Incidentally Noted on Chest Multi-Detector Computed Tomography: A Multicentre Experience
Current Vascular Pharmacology Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies
Mini-Reviews in Medicinal Chemistry MET and ALK as Targets for the Treatment of NSCLC
Current Pharmaceutical Design The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry New Framework for the Discovery of PRC2 Inhibitors: Epigenetic Drugs
Current Drug Targets Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry Biological Denitrification: Screening of Packing Material, Comparison of Denitrification Rate by Pseudomonas aeruginosa and Pseudomonas stutzeri, Application and Design of Bioreactor
Current Environmental Engineering Alpha-Interferon and Its Effects on Signalling Pathways Within Cells
Current Protein & Peptide Science Recent Progress in Gene Therapy and Other Targeted Therapeutic Approaches for Beta Thalassemia
Current Drug Targets Melatonin and Aromatase in Breast Cancer
Clinical Cancer Drugs In Vivo Models of Childhood Leukemia for Preclinical Drug Testing
Current Drug Targets